NDAINTRAVENOUSINJECTABLE
Approved
Jul 2001
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
6
Data completeness
5/8 — Partial
DEFINITY (perflutren) by Lantheus Medical Imaging is ultrasound contrast activity [moa]. Approved for coronary artery disease, cardiac disease. First approved in 2001.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DEFINITY (perflutren) is an intravenous ultrasound contrast agent that enhances visualization of cardiac structures and blood flow in real-time imaging. It works by creating microbubbles that reflect ultrasound waves, improving image quality for diagnosis of coronary artery disease and other cardiac conditions. The drug enables clinicians to assess cardiac perfusion and function with greater diagnostic accuracy than unenhanced ultrasound.
Peak11.0 years to LOE
DEFINITY remains at peak commercial maturity with established market presence; the brand team likely operates with stable staffing and focused on retention rather than aggressive growth.
Mechanism of Action
Ultrasound Contrast Activity
Pharmacologic Class:
Contrast Agent for Ultrasound Imaging
Indications (2)
Worked on DEFINITY at Lantheus Medical Imaging? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.